Last reviewed · How we verify
Amneal Pharmaceuticals, LLC — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
2 Phase 3
0 Phase 2
2 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Diclofenac Sodium Topical Gel, 1% | Diclofenac Sodium Topical Gel, 1% | marketed | Nonsteroidal anti-inflammatory drug (NSAID) | Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) | Pain Management / Rheumatology | |
| Voltaren Topical Gel, 1% | Voltaren Topical Gel, 1% | phase 3 | NSAID | COX | Musculoskeletal | |
| Vehicle Diclofenac Sodium Topical Gel | Vehicle Diclofenac Sodium Topical Gel | phase 3 | NSAID | COX-2 | Pain Management |
Therapeutic area mix
- Musculoskeletal · 1
- Pain Management · 1
- Pain Management / Rheumatology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Organon and Co · 2 shared drug classes
- Iroko Pharmaceuticals, LLC · 2 shared drug classes
- Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 shared drug classes
- Noven Pharmaceuticals, Inc. · 2 shared drug classes
- Pfizer · 2 shared drug classes
- Apsen Farmaceutica S.A. · 1 shared drug class
- Antibe Therapeutics Inc. · 1 shared drug class
- Allergan · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Amneal Pharmaceuticals, LLC:
- Amneal Pharmaceuticals, LLC pipeline updates — RSS
- Amneal Pharmaceuticals, LLC pipeline updates — Atom
- Amneal Pharmaceuticals, LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Amneal Pharmaceuticals, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/amneal-pharmaceuticals-llc. Accessed 2026-05-16.